A Look At AbCellera Biologics (ABCL) Valuation As ABCL-635 Advances Into Phase II Trials

AbCellera Biologics (ABCL) has moved into focus after advancing its lead program, ABCL-635, into Phase II trials for a non-hormonal treatment of vasomotor symptoms in women, alongside recent shifts in analyst earnings expectations.

See our latest analysis for AbCellera Biologics.

The recent move of ABCL-635 into Phase II, alongside the latest earnings update, comes after a 90-day share price return of 31.94% and a 1-year total shareholder return of 101.48%, although the stock has seen short term weakness with the 7-day share price return down 21.95%.

If you are following how clinical and AI driven drug discovery stories are trading, it can help to look across the sector and see what else is gaining attention through 32 healthcare AI stocks

With AbCellera shares up sharply over 1 year, yet trading at a steep discount to the average analyst price target of US$10.14, investors now face a key question: is this a genuine opportunity or is the market already pricing in future growth?

Most Popular Narrative: 58.4% Undervalued

At a last close of $4.09 against a most-followed fair value estimate of $9.83, the current pricing sits well below that narrative benchmark.

The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long-term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

Read the complete narrative.

Curious what kind of revenue ramp, margin shift, and future earnings multiple sit behind that fair value figure? The narrative leans on sizeable top line assumptions, a step change in profitability, and a valuation multiple more often associated with fast growing leaders. The full story spells out how those pieces are expected to fit together.

Result: Fair Value of $9.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story can change quickly if high R&D spending keeps net losses elevated or if ABCL635 and partnered programs fail to deliver expected clinical or commercial traction.

Find out about the key risks to this AbCellera Biologics narrative.

Another Angle On Valuation

The fair value narrative points to AbCellera at $9.83 per share, yet the current P/S ratio of 15.8x sits far above the US Life Sciences industry at 3.5x, the peer average at 7.6x, and a fair ratio of just 0.3x. That gap raises a simple question: is the story or the multiples more likely to shift first?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and sentiment running in both directions, it makes sense to look at the full picture quickly and decide where you stand by using the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If AbCellera has caught your attention, do not stop here. Broader ideas across sectors can sharpen your watchlist and highlight opportunities you might otherwise miss.

• Spot potential value opportunities early by checking out 50 high quality undervalued stocks that combine quality fundamentals with lower market expectations.
• Strengthen your defense with 66 resilient stocks with low risk scores that score well on resilience and business stability.
• Get ahead of the crowd by scanning the screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com